FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform

Mayer, Julie Ann; Pham, Tam N.; Wong, Karina; Scoggin, Jayne; Sales, Edgar; Clarin, Trisky; Pircher, Tony J.; Mikolajczyk, Stephen D.; Cotter, Philip D.; Bischoff, Farideh Z.

doi:10.1016/j.cancergen.2011.10.011

Cited by 69 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This automated CTC detection procedure is completed in 105 min. Based on this result, we considered that the automated system could be applied not only to CTC detection but also to other image-based molecular analysis of CTCs including the screening of novel CTC markers and FISHbased gene mutation analysis with further improvements of treatment conditions (Lim et al, 2012;Mayer et al, 2011;Zhao et al, 2013). In addition, by combining the single cell isolation technique by using micromanipulation system with the proposed system Hosokawa et al, 2009), more detailed molecular analysis such as the detection of gene mutation could be performed at the single-cell level.…”

Section: Evaluation Of Ctc Detection Processes and Detection Sensitivmentioning

confidence: 98%

Development of the automated circulating tumor cell recovery system with microcavity array

Negishi

Hosokawa

Nakamura

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Section: Evaluation Of Ctc Detection Processes and Detection Sensitivmentioning

confidence: 98%

Development of the automated circulating tumor cell recovery system with microcavity array

Negishi

Hosokawa

Nakamura

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

“…Recently, two Bio-MEMS and microfluidic-based systems have been reported for FISH assays. For instance, Mayer et al employed an OncoCEETM microchannel technology to a pilot clinical trial for FISH detection of HER2 (Mayer et al, 2011). The adequate sensitivity and specificity of the OncoCEE TM microchannel were demonstrated in this work.…”

Section: Introductionmentioning

confidence: 72%

A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells

Kao

Tai

Chang

et al. 2015

Biosensors and Bioelectronics

View full text Add to dashboard Cite

“…Affibodies are a nonimmunoglobulin scaffold, consisting of a three-helix bundle, selected for high-affinity binding through phage display, and easily expressed in E. coli (21). The initial affibody we modified bound strongly and specifically to epidermal growth factor receptor (EGFR) (21), a tyrosine kinase expressed on many cancer cells and a target antigen in CTC isolation (22,23). We inserted KTag at the N terminus of the affibody and SpyTag at the C terminus (i.e., KTag-AffiEGFRSpyTag) so that covalent ligation between KTag and SpyTag would generate chains (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…To demonstrate the generality of this SpyLigase approach, we tested a second affibody, binding with high affinity to HER2 (an important tyrosine kinase cancer antigen, also known as ErbB2 or Neu) (23,24). KTag-AffiHER2-SpyTag was similarly polymerized by SpyLigase, forming high molecular weight species extending to more than 20 affibody units (Fig.…”

Section: Resultsmentioning

confidence: 99%

SpyLigase peptide–peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture

Fierer

Veggiani

Howarth

2014

Proc. Natl. Acad. Sci. U.S.A.

155

162

View full text Add to dashboard Cite

Individual proteins can now often be modified with atomic precision, but there are still major obstacles to connecting proteins into larger assemblies. To direct protein assembly, ideally, peptide tags would be used, providing the minimal perturbation to protein function. However, binding to peptides is generally weak, so assemblies are unstable over time and disassemble with force or harsh conditions. We have recently developed an irreversible protein-peptide interaction (SpyTag/SpyCatcher), based on a protein domain from Streptococcus pyogenes, that locks itself together via spontaneous isopeptide bond formation. Here we develop irreversible peptide-peptide interaction, through redesign of this domain and genetic dissection into three parts: a protein domain termed SpyLigase, which now ligates two peptide tags to each other. All components expressed efficiently in Escherichia coli and peptide tags were reactive at the N terminus, at the C terminus, or at internal sites. Peptide-peptide ligation enabled covalent and site-specific polymerization of affibodies or antibodies against the tumor markers epidermal growth factor receptor (EGFR) and HER2. Magnetic capture of circulating tumor cells (CTCs) is one of the most promising approaches to improve cancer prognosis and management, but CTC capture is limited by inefficient recovery of cells expressing low levels of tumor antigen. SpyLigase-assembled protein polymers made possible the isolation of cancerous cells expressing lower levels of tumor antigen and should have general application in enhancing molecular capture.bionanotechnology | synthetic biology | metastasis | antibody | nanobiotechnology

show abstract

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform

Cited by 69 publications

References 25 publications

Development of the automated circulating tumor cell recovery system with microcavity array

Development of the automated circulating tumor cell recovery system with microcavity array

A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells

SpyLigase peptide–peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture

Contact Info

Product

Resources

About